These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants]. de Winter JP, Egberts J, de Kleine MJ, van Bel F, Wijnands JB, Guit GL. Ned Tijdschr Geneeskd; 1992 Oct 10; 136(41):2018-24. PubMed ID: 1407193 [Abstract] [Full Text] [Related]
7. [Effect of 2 different dosages of a porcine surfactant on pulmonary gas exchange of premature infants with severe respiratory distress syndrome]. Herting E, Tubman R, Halliday HL, Harms K, Speer CP, Curstedt T, Robertson B. Monatsschr Kinderheilkd; 1993 Sep 10; 141(9):721-7. PubMed ID: 8413348 [Abstract] [Full Text] [Related]
8. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R, Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. Pediatrics; 2005 Apr 10; 115(4):1030-8. PubMed ID: 15805381 [Abstract] [Full Text] [Related]
13. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome. Fujii A, Allen R, Doros G, O'Brien S. J Perinatol; 2010 Oct 01; 30(10):671-6. PubMed ID: 20336077 [Abstract] [Full Text] [Related]